BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 30411263)

  • 1. Minimal Residual Disease in Acute Myeloid Leukemia.
    Gomez-Arteaga A; Guzman ML
    Adv Exp Med Biol; 2018; 1100():111-125. PubMed ID: 30411263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
    Blackmon AL; Hourigan CS
    Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization.
    Schuurhuis GJ; Ossenkoppele GJ; Kelder A; Cloos J
    Expert Rev Hematol; 2018 Dec; 11(12):921-935. PubMed ID: 30466339
    [No Abstract]   [Full Text] [Related]  

  • 6. Methods of Detection of Measurable Residual Disease in AML.
    Zhou Y; Wood BL
    Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
    Xiao W; Petrova-Drus K; Roshal M
    Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
    Heuser M; Freeman SD; Ossenkoppele GJ; Buccisano F; Hourigan CS; Ngai LL; Tettero JM; Bachas C; Baer C; Béné MC; Bücklein V; Czyz A; Denys B; Dillon R; Feuring-Buske M; Guzman ML; Haferlach T; Han L; Herzig JK; Jorgensen JL; Kern W; Konopleva MY; Lacombe F; Libura M; Majchrzak A; Maurillo L; Ofran Y; Philippe J; Plesa A; Preudhomme C; Ravandi F; Roumier C; Subklewe M; Thol F; van de Loosdrecht AA; van der Reijden BA; Venditti A; Wierzbowska A; Valk PJM; Wood BL; Walter RB; Thiede C; Döhner K; Roboz GJ; Cloos J
    Blood; 2021 Dec; 138(26):2753-2767. PubMed ID: 34724563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
    Fuda F; Chen W
    Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introducing minimal residual disease in acute myeloid leukemia.
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mind map for managing minimal residual disease in acute myeloid leukemia.
    Benton CB; Ravandi F
    Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.
    Wood BL
    Curr Protoc Cytom; 2020 Jun; 93(1):e73. PubMed ID: 32311834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
    Aitken MJL; Ravandi F; Patel KP; Short NJ
    J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of multiparameter flow cytometry for disease monitoring in AML.
    Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
    Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
    Lacombe F; Campos L; Allou K; Arnoulet C; Delabarthe A; Dumezy F; Feuillard J; Geneviève F; Guérin E; Guy J; Jouault H; Lepelley P; Maynadié M; Solly F; Ballon OW; Preudhomme C; Baruchel A; Dombret H; Ifrah N; Béné MC;
    Hematol Oncol; 2018 Apr; 36(2):422-428. PubMed ID: 29218734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
    Rossi G; Giambra V; Minervini MM; De Waure C; Mancinelli S; Ciavarella M; Sinisi NP; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2020 May; 98(3):216-225. PubMed ID: 31697027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.